JP2002539072A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002539072A5 JP2002539072A5 JP2000565908A JP2000565908A JP2002539072A5 JP 2002539072 A5 JP2002539072 A5 JP 2002539072A5 JP 2000565908 A JP2000565908 A JP 2000565908A JP 2000565908 A JP2000565908 A JP 2000565908A JP 2002539072 A5 JP2002539072 A5 JP 2002539072A5
- Authority
- JP
- Japan
- Prior art keywords
- egf
- antagonist
- formulated
- package
- growth factor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000001301 EGF receptor Human genes 0.000 description 31
- 108060006698 EGF receptor Proteins 0.000 description 31
- 239000005557 antagonist Substances 0.000 description 20
- 238000000034 method Methods 0.000 description 8
- 210000003097 mucus Anatomy 0.000 description 8
- 238000009472 formulation Methods 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 239000003814 drug Substances 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 5
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003172 expectorant agent Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 4
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 4
- 150000004917 tyrosine kinase inhibitor derivatives Chemical group 0.000 description 4
- 101800003838 Epidermal growth factor Proteins 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 230000000692 anti-sense effect Effects 0.000 description 3
- 229940124630 bronchodilator Drugs 0.000 description 3
- 239000003246 corticosteroid Substances 0.000 description 3
- 229940116977 epidermal growth factor Drugs 0.000 description 3
- 230000003419 expectorant effect Effects 0.000 description 3
- 238000010874 in vitro model Methods 0.000 description 3
- 230000000510 mucolytic effect Effects 0.000 description 3
- 230000000241 respiratory effect Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000009969 flowable effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 239000000168 bronchodilator agent Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 229940112141 dry powder inhaler Drugs 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 229940066493 expectorants Drugs 0.000 description 1
- 210000002175 goblet cell Anatomy 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229940071648 metered dose inhaler Drugs 0.000 description 1
- 229940066491 mucolytics Drugs 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9702398P | 1998-08-18 | 1998-08-18 | |
| US60/097,023 | 1998-08-18 | ||
| PCT/US1999/018696 WO2000010588A2 (en) | 1998-08-18 | 1999-08-17 | Epidermal growth factor receptor antagonists for treating hypersecretion of mucus in the lungs |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009123658A Division JP2009221212A (ja) | 1998-08-18 | 2009-05-22 | Ｅｇｆ−ｒアンタゴニストの投与による気道粘液産生の防止 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002539072A JP2002539072A (ja) | 2002-11-19 |
| JP2002539072A5 true JP2002539072A5 (enExample) | 2006-01-05 |
Family
ID=22260380
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000565908A Pending JP2002539072A (ja) | 1998-08-18 | 1999-08-17 | Ｅｇｆ−ｒアンタゴニストの投与による気道粘液産生の防止 |
| JP2009123658A Pending JP2009221212A (ja) | 1998-08-18 | 2009-05-22 | Ｅｇｆ−ｒアンタゴニストの投与による気道粘液産生の防止 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009123658A Pending JP2009221212A (ja) | 1998-08-18 | 2009-05-22 | Ｅｇｆ−ｒアンタゴニストの投与による気道粘液産生の防止 |
Country Status (35)
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100609646B1 (ko) | 1998-08-18 | 2006-08-04 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | Ｅｇｆ-ｒ 길항물질의 투여에 의한 기도 점액생산의 방지 |
| US7354894B2 (en) | 1998-08-18 | 2008-04-08 | The Regents Of The University Of California | Preventing airway mucus production by administration of EGF-R antagonists |
| US6846799B1 (en) * | 1998-08-18 | 2005-01-25 | The Regents Of The University Of California | Preventing airway mucus production by administration of EGF-R antagonists |
| US20030236300A1 (en) * | 1999-10-27 | 2003-12-25 | Yale University | Conductance of improperly folded proteins through the secretory pathway and related methods for treating disease |
| US20030149113A1 (en) * | 2001-10-12 | 2003-08-07 | Caplan Michael J. | Conductance of improperly folded proteins through the secretory pathway and related methods for treating disease |
| WO2002094318A1 (en) * | 2001-05-18 | 2002-11-28 | University Of Southern California | Vector for targeted delivery to cells |
| US6818446B2 (en) | 2001-11-21 | 2004-11-16 | The Regents Of The University Of California | Compositions and methods for the analysis of mucin gene expression and identification of drugs having the ability to inhibit mucin gene expression |
| DE10204462A1 (de) * | 2002-02-05 | 2003-08-07 | Boehringer Ingelheim Pharma | Verwendung von Tyrosinkinase-Inhibitoren zur Behandlung inflammatorischer Prozesse |
| US6924285B2 (en) * | 2002-03-30 | 2005-08-02 | Boehringer Ingelheim Pharma Gmbh & Co. | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them |
| AU2003221767B2 (en) * | 2002-04-24 | 2008-07-31 | Research Development Foundation | Synergistic effects of nuclear transcription factor NF-kB inhibitors and anti-neoplastic agents |
| AU2003253681B2 (en) * | 2002-06-24 | 2008-05-01 | Research Development Foundation | Treatment of human multiple myeloma by Curcumin |
| WO2004066912A2 (en) * | 2003-01-31 | 2004-08-12 | Technion Research & Development Foundation Ltd. | Anti-inflammatory compositions and uses thereof |
| US7195899B1 (en) * | 2003-03-14 | 2007-03-27 | Florida State University Research Foundation, Inc. | Cell-based biosensor for harmful airborne agents |
| CA2536380A1 (en) | 2003-08-26 | 2005-02-26 | Research Development Foundation | Osteoclastogenesis inhibitors and uses thereof |
| CA2536738A1 (en) * | 2003-08-26 | 2005-03-10 | Research Development Foundation | Aerosol delivery of curcumin |
| US20060115523A1 (en) * | 2004-12-01 | 2006-06-01 | Konduri Kameswari S | Sterically stabilized liposome and triamcinolone composition for treating the respiratory tract of a mammal |
| US11324698B2 (en) | 2003-08-28 | 2022-05-10 | Vgsk Technologies, Inc. | Sterically stabilized carrier for aerosol therapeutics, compositions and methods for treating the respiratory tract of a mammal |
| US8846079B1 (en) | 2004-12-01 | 2014-09-30 | Vgsk Technologies, Inc. | Sterically stabilized carrier for aerosol therapeutics, compositions and methods for treating the respiratory tract of a mammal |
| US20050096332A1 (en) * | 2003-10-30 | 2005-05-05 | Boehringer Ingelheim International Gmbh | Use of tyrosine kinase inhibitors for the treatment of inflammatory processes |
| EP2251357A1 (en) | 2003-11-07 | 2010-11-17 | Ablynx N.V. | Camelidae single domain antibodies VHH directed against epidermal growth factor receptor and uses therefor |
| US8134010B2 (en) * | 2004-05-05 | 2012-03-13 | Renopharm Ltd. | Thiazole-based nitric oxide donors having aryl substituent(s) and uses thereof |
| US7498445B2 (en) * | 2004-05-05 | 2009-03-03 | Renopharm Ltd. | Thiazole-based nitric oxide donors capable of releasing two or more nitric oxide molecules and uses thereof |
| EP1753734A1 (en) * | 2004-05-05 | 2007-02-21 | Renopharm Ltd. | Nitric oxide donors and uses thereof |
| US7968575B2 (en) * | 2004-05-05 | 2011-06-28 | Renopharm Ltd. | Nitric oxide donors and uses thereof |
| US6998028B1 (en) * | 2004-09-24 | 2006-02-14 | Superpower, Inc. | Methods for forming superconducting conductors |
| US7915223B2 (en) * | 2004-09-27 | 2011-03-29 | Technion Research & Development Foundation Ltd. | Antimicrobial agents |
| AU2005288519A1 (en) * | 2004-09-27 | 2006-04-06 | Technion Research & Development Foundation Ltd. | Fatty acid modified polylysines as antimicrobial agents |
| WO2006035706A1 (ja) * | 2004-09-28 | 2006-04-06 | Dainippon Ink And Chemicals, Inc. | 薬効評価用動物、薬効評価用動物の慢性閉塞性肺疾患発症方法及びその動物を用いた薬効評価方法 |
| JP4690158B2 (ja) * | 2004-09-28 | 2011-06-01 | スギ生物科学研究所株式会社 | 薬効評価用動物、薬効評価用動物の慢性閉塞性肺疾患発症方法及びその動物を用いた薬効評価方法 |
| WO2007047235A2 (en) * | 2005-10-11 | 2007-04-26 | Washington University | Compositions and methods for treatment of airway hypersecretion |
| EP1921070A1 (de) * | 2006-11-10 | 2008-05-14 | Boehringer Ingelheim Pharma GmbH & Co. KG | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung |
| WO2008095847A1 (de) * | 2007-02-06 | 2008-08-14 | Boehringer Ingelheim International Gmbh | Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
| US20080293740A1 (en) * | 2007-04-03 | 2008-11-27 | Parion Sciences, Inc. | Method of treating acid-sensing ion channel mediated pain, cough suppression, and central nervous system disorders |
| WO2008132738A2 (en) * | 2007-04-30 | 2008-11-06 | Technion Research & Development Foundation Ltd. | Anticancerous polymeric agents |
| EP2152289A1 (en) * | 2007-04-30 | 2010-02-17 | Technion Research & Development Foundation Ltd. | Novel antimicrobial agents |
| WO2009098061A1 (de) * | 2008-02-07 | 2009-08-13 | Boehringer Ingelheim International Gmbh | Spirocyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
| US8648191B2 (en) * | 2008-08-08 | 2014-02-11 | Boehringer Ingelheim International Gmbh | Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them |
| US8112365B2 (en) * | 2008-12-19 | 2012-02-07 | Foster Scott C | System and method for online employment recruiting and evaluation |
| WO2010085665A2 (en) | 2009-01-23 | 2010-07-29 | Cedars-Sinai Medical Center | Targeted delivery system |
| US9095606B1 (en) | 2010-11-13 | 2015-08-04 | Sirbal Ltd. | Molecular and herbal combinations for treating psoriasis |
| US8734859B1 (en) | 2010-11-13 | 2014-05-27 | Sirbal Ltd. | Molecular combinations for cancer or other disease treatment |
| US9066974B1 (en) | 2010-11-13 | 2015-06-30 | Sirbal Ltd. | Molecular and herbal combinations for treating psoriasis |
| US8541382B2 (en) | 2010-11-13 | 2013-09-24 | Sirbal Ltd. | Cardiac glycoside analogs in combination with emodin for cancer therapy |
| JP6527305B2 (ja) * | 2011-01-10 | 2019-06-05 | インヴィオン， インコーポレイテッド | 禁煙のためのβ−アドレナリン作動性インバースアゴニストの使用 |
| US20170049687A1 (en) | 2015-07-29 | 2017-02-23 | Sirbal Ltd. | Herbal Combinations For Treating Scalp Conditions |
| US10036009B2 (en) | 2012-08-03 | 2018-07-31 | Cedars-Sinai Medical Center | Isolating traffic-enhancing mutants of drug delivery protein |
| AU2014296032A1 (en) | 2013-07-31 | 2016-03-17 | Windward Pharma, Inc. | Aerosol tyrosine kinase inhibitor compounds and uses thereof |
| EP3498288A1 (en) | 2013-12-02 | 2019-06-19 | Sirbal Ltd. | Herbal combinations for treatment of a skin condition |
| WO2017048860A1 (en) | 2015-09-14 | 2017-03-23 | Vgsk Technologies, Inc. | A sterically stabilized carrier for subcutaneous, sublingual and oral therapeutics, compositions and methods for treating a mammal |
| WO2022187563A1 (en) * | 2021-03-03 | 2022-09-09 | Georgia Tech Research Corporation | Cell culture growth apparatus and method of underside attachment to a surface using cell seeding |
| CA3217928A1 (en) | 2021-05-05 | 2022-11-10 | Kameswari S. Konduri | Liposome-encapsulated corticosteriods inhibit sars-cov-2 replication and reduces lung inflammation |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2932481A (en) * | 1954-06-15 | 1960-04-12 | Breer | Bipod camera support |
| GB1242211A (en) * | 1967-08-08 | 1971-08-11 | Fisons Pharmaceuticals Ltd | Pharmaceutical composition |
| FR2502627A1 (fr) * | 1981-02-02 | 1982-10-01 | Refarmed Sa | Derives thioliques de l'erythromycine a activite therapeutique, procede de preparation et produits pharmaceutiques dans lesquels ils apparaissent |
| IT1173549B (it) * | 1984-04-02 | 1987-06-24 | Corvi Camillo Spa | Estere dell'acido teofillin-7-acetico con il d,l-trans-sobrerolo avente attivita' mucosecretolitica-fluidificante e antibroncospastica, procedimento per la sua preparazione e sue composizioni farmaceutiche |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4904786A (en) * | 1986-01-27 | 1990-02-27 | American Home Products Corporation | Quinoline compounds as antiallergic and antiinflammatory agents |
| US5089516A (en) * | 1987-03-11 | 1992-02-18 | Kanegafuchi Kagaku Kogyo Kabushiki Kaisha | 1-phenyl-3,5-pyrazolidinedione hydroxystyrene compounds which have tyrosine kinase inhibiting activity |
| US5217999A (en) | 1987-12-24 | 1993-06-08 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Styryl compounds which inhibit EGF receptor protein tyrosine kinase |
| WO1990003374A1 (en) * | 1988-09-28 | 1990-04-05 | The Upjohn Company | 1,4-dihydrothionapthoquinone and heterocyclic congeners which inhibit lipoxygenase enzymes |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| GB8904009D0 (en) | 1989-02-22 | 1989-04-05 | Celltech Ltd | Vector |
| US5362755A (en) * | 1990-01-05 | 1994-11-08 | Sepracor, Inc. | Method for treating asthma using optically pure (R)-albuterol |
| US5302606A (en) * | 1990-04-16 | 1994-04-12 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Styryl-substituted pyridyl compounds which inhibit EGF receptor tyrosine kinase |
| US5165424A (en) | 1990-08-09 | 1992-11-24 | Silverman Harvey N | Method and system for whitening teeth |
| US5404871A (en) | 1991-03-05 | 1995-04-11 | Aradigm | Delivery of aerosol medications for inspiration |
| CZ282603B6 (cs) * | 1991-03-06 | 1997-08-13 | Merck Patent Gesellschaft Mit Beschränkter Haftun G | Humanizované a chimerické monoklonální protilátky |
| US5116616A (en) * | 1991-04-29 | 1992-05-26 | Bio-Technology General Corp. | Use of intratracheal administration of SOD to protect humans from lung injury due to hyperoxia and hyperventilation |
| DE4117078A1 (de) * | 1991-05-25 | 1992-11-26 | Boehringer Ingelheim Kg | Verfahren zur herstellung therapeutisch anwendbarer aerosole |
| ES2284226T3 (es) | 1991-07-02 | 2007-11-01 | Nektar Therapeutics | Dispositivo para proporcionar medicamentos en aerosol. |
| PT100905A (pt) * | 1991-09-30 | 1994-02-28 | Eisai Co Ltd | Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem |
| DE4310051A1 (de) | 1992-04-11 | 1993-10-14 | Byk Gulden Lomberg Chem Fab | Weitere Verwendung substituierter Pyridazine |
| US5785049A (en) | 1994-09-21 | 1998-07-28 | Inhale Therapeutic Systems | Method and apparatus for dispersion of dry powder medicaments |
| JP2801085B2 (ja) * | 1992-09-11 | 1998-09-21 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | ヒト細胞を植えた気道上の異種移植片を有する非ヒト動物 |
| IL108367A0 (en) * | 1993-01-27 | 1994-04-12 | Hektoen Inst For Medical Resea | Antisense polynzcleotide inhibition of human growth factor-sensitive cancer cells |
| US5497763A (en) | 1993-05-21 | 1996-03-12 | Aradigm Corporation | Disposable package for intrapulmonary delivery of aerosolized formulations |
| US5886026A (en) * | 1993-07-19 | 1999-03-23 | Angiotech Pharmaceuticals Inc. | Anti-angiogenic compositions and methods of use |
| GB9314893D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
| GB9314884D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Tricyclic derivatives |
| AU7623194A (en) | 1993-09-03 | 1995-03-22 | Vpi Holdings Ltd. | Oligonucleotides with rna cleavage activity |
| DE69414405T2 (de) * | 1993-09-13 | 1999-06-10 | Merck Frosst Canada Inc., Kirkland, Quebec | Verfahren zur messung metaplastischer veränderungen von schleimabsondernden epithelzellen |
| CA2261433A1 (en) * | 1993-12-09 | 1995-06-10 | Belinda Sanchez Ramirez | Composition comprising autologous epidermal growth factor |
| AU706417B2 (en) | 1994-02-23 | 1998-06-17 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for inhibiting the expression of disease related genes |
| WO1995024190A2 (en) | 1994-03-07 | 1995-09-14 | Sugen, Inc. | Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof |
| US20030114379A1 (en) * | 1994-03-08 | 2003-06-19 | Human Genome Sciences, Inc. | Methods of treating or preventing cell, tissue, and organ damage using human myeloid progenitor inhibitory factor-1 (MPIF-1) |
| GB9510757D0 (en) * | 1994-09-19 | 1995-07-19 | Wellcome Found | Therapeuticaly active compounds |
| CA2216796C (en) | 1995-03-30 | 2003-09-02 | Pfizer Inc. | Quinazoline derivatives |
| GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| GB9508565D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quiazoline derivative |
| EP0824525B1 (en) | 1995-04-27 | 2001-06-13 | AstraZeneca AB | Quinazoline derivatives |
| US5747498A (en) * | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| GB9523675D0 (en) * | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
| US5760041A (en) | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
| EA001595B1 (ru) * | 1996-04-12 | 2001-06-25 | Варнер-Ламберт Компани | Необратимые ингибиторы тирозинкиназ |
| EP0918461B1 (en) * | 1996-07-29 | 2004-10-27 | Paringenix, Inc. | Methods of treating asthma with o-desulfated heparin |
| SE9603725D0 (sv) | 1996-10-11 | 1996-10-11 | Astra Ab | New teatment |
| UA73073C2 (uk) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
| ZA986729B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitors of tyrosine kinases |
| ZA986732B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
| US6251912B1 (en) * | 1997-08-01 | 2001-06-26 | American Cyanamid Company | Substituted quinazoline derivatives |
| TW436485B (en) | 1997-08-01 | 2001-05-28 | American Cyanamid Co | Substituted quinazoline derivatives |
| JP2001526230A (ja) * | 1997-12-19 | 2001-12-18 | スミスクライン・ビーチャム・コーポレイション | ヘテロアリール置換イミダゾール化合物、その医薬組成物および使用 |
| CA2322311C (en) * | 1998-03-04 | 2009-10-13 | Bristol-Myers Squibb Company | Heterocyclo-substituted imidazopyrazine protein tyrosine kinase inhibitors |
| US5968748A (en) * | 1998-03-26 | 1999-10-19 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of human HER-2 expression |
| KR100609646B1 (ko) | 1998-08-18 | 2006-08-04 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | Ｅｇｆ-ｒ 길항물질의 투여에 의한 기도 점액생산의 방지 |
| US6297258B1 (en) * | 1998-09-29 | 2001-10-02 | American Cyanamid Company | Substituted 3-cyanoquinolines |
| US6288082B1 (en) * | 1998-09-29 | 2001-09-11 | American Cyanamid Company | Substituted 3-cyanoquinolines |
| WO2000051991A1 (en) | 1999-02-27 | 2000-09-08 | Boehringer Ingelheim Pharma Kg | 4-AMINO-QUINAZOLINE AND QUINOLINE DERIVATIVES HAVING AN INHIBITORY EFFECT ON SIGNAL TRANsSDUCTION MEDIATED BY TYROSINE KINASES |
| EP1226136B1 (en) * | 1999-10-19 | 2004-12-29 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| JP4939716B2 (ja) | 2000-04-08 | 2012-05-30 | ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | 二環式複素環化合物、これらの化合物を含む医薬組成物、それらの使用及びそれらの調製方法 |
| US6627634B2 (en) | 2000-04-08 | 2003-09-30 | Boehringer Ingelheim Pharma Kg | Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them |
-
1999
- 1999-08-17 KR KR1020017002114A patent/KR100609646B1/ko not_active Expired - Fee Related
- 1999-08-17 NZ NZ509271A patent/NZ509271A/en not_active IP Right Cessation
- 1999-08-17 SI SI9931016T patent/SI1119349T1/sl unknown
- 1999-08-17 US US09/375,597 patent/US6270747B1/en not_active Expired - Lifetime
- 1999-08-17 EE EEP200100097A patent/EE200100097A/xx unknown
- 1999-08-17 TW TW088114306A patent/TWI250019B/zh not_active IP Right Cessation
- 1999-08-17 SK SK216-2001A patent/SK287805B6/sk not_active IP Right Cessation
- 1999-08-17 BR BR9912672-9A patent/BR9912672A/pt not_active IP Right Cessation
- 1999-08-17 CA CA2337422A patent/CA2337422C/en not_active Expired - Fee Related
- 1999-08-17 EA EA200100136A patent/EA004316B1/ru not_active IP Right Cessation
- 1999-08-17 JP JP2000565908A patent/JP2002539072A/ja active Pending
- 1999-08-17 RS YU13201A patent/RS50273B/sr unknown
- 1999-08-17 ES ES99943729T patent/ES2310047T3/es not_active Expired - Lifetime
- 1999-08-17 PT PT99943729T patent/PT1119349E/pt unknown
- 1999-08-17 AU AU56766/99A patent/AU760766B2/en not_active Ceased
- 1999-08-17 EP EP08009498A patent/EP1970058A1/en not_active Withdrawn
- 1999-08-17 UA UA2001021134A patent/UA73722C2/uk unknown
- 1999-08-17 CZ CZ2001584A patent/CZ2001584A3/cs unknown
- 1999-08-17 CN CNB998095745A patent/CN1184961C/zh not_active Expired - Fee Related
- 1999-08-17 AT AT99943729T patent/ATE399541T1/de active
- 1999-08-17 HU HU0103894A patent/HUP0103894A3/hu unknown
- 1999-08-17 ID IDW20010322A patent/ID27345A/id unknown
- 1999-08-17 EP EP99943729A patent/EP1119349B1/en not_active Expired - Lifetime
- 1999-08-17 DE DE69939022T patent/DE69939022D1/de not_active Expired - Lifetime
- 1999-08-17 HR HR20010119A patent/HRP20010119B1/xx not_active IP Right Cessation
- 1999-08-17 DK DK99943729T patent/DK1119349T3/da active
- 1999-08-17 WO PCT/US1999/018696 patent/WO2000010588A2/en not_active Ceased
- 1999-08-17 TR TR2001/00560T patent/TR200100560T2/xx unknown
- 1999-08-17 IL IL14085599A patent/IL140855A0/xx active IP Right Grant
- 1999-08-17 PL PL351765A patent/PL200940B1/pl not_active IP Right Cessation
- 1999-08-18 MY MYPI99003537A patent/MY126490A/en unknown
- 1999-08-18 CO CO99052263A patent/CO5130028A1/es unknown
- 1999-08-19 AR ARP990104149A patent/AR020220A1/es not_active Application Discontinuation
-
2001
- 2001-01-10 IL IL140855A patent/IL140855A/en not_active IP Right Cessation
- 2001-02-14 NO NO20010749A patent/NO327000B1/no not_active IP Right Cessation
- 2001-02-26 US US09/794,232 patent/US6566324B2/en not_active Expired - Lifetime
- 2001-05-24 US US09/865,239 patent/US6551989B2/en not_active Expired - Lifetime
-
2003
- 2003-02-07 US US10/359,932 patent/US7358222B2/en not_active Expired - Fee Related
- 2003-02-07 US US10/359,982 patent/US8048844B1/en not_active Expired - Fee Related
-
2008
- 2008-02-27 US US12/038,718 patent/US8071074B2/en not_active Expired - Fee Related
- 2008-09-26 CY CY20081101062T patent/CY1110370T1/el unknown
-
2009
- 2009-05-22 JP JP2009123658A patent/JP2009221212A/ja active Pending
-
2010
- 2010-07-21 PH PH12010000215A patent/PH12010000215A1/en unknown
- 2010-07-21 PH PH12010000216A patent/PH12010000216A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002539072A5 (enExample) | ||
| CA2337422A1 (en) | Preventing airway mucus production by administration of egf-r antagonists | |
| Scheuch et al. | Clinical perspectives on pulmonary systemic and macromolecular delivery | |
| EP2914269B1 (en) | Galactoside inhibitor of galectin-3 and its use for treating pulmonary fibrosis | |
| Siekmeier et al. | Systemic treatment by inhalation of macromolecules–principles, problems, and examples | |
| US9580456B2 (en) | Galactoside inhibitor of galectin-3 and its use for treating pulmonary fibrosis | |
| US20090123422A1 (en) | Method of treating idiopathic pulmonary fibrosis with aerosolized IFN-y | |
| US9301994B2 (en) | LIGHT inhibitors for asthma, lung and airway inflammation, respiratory, interstitial, pulmonary and fibrotic disease treatment | |
| JPH09501700A (ja) | 気道流路および肺疾患の処置のためのモメタゾンフロエートの使用 | |
| Sanjar et al. | Treating systemic diseases via the lung | |
| JP2003531123A (ja) | 医薬品 | |
| CN115427576B (zh) | 包括透明质酸和蛋白聚糖连接蛋白1的用于预防或治疗肺部疾病的组合物 | |
| CN101856327A (zh) | 一种苯环喹溴铵定量吸入气雾剂及制备方法 | |
| KR102875179B1 (ko) | 폴리클로날 면역글로불린을 사용한 급성 악화를 예방하거나 치료하기 위한 방법 및 조성물 | |
| WO2022006091A1 (en) | Biopharmaceutical formulation of anti-pd-1, anti-pd-l1, and anti-vegfr therapeutic monoclonal antibodies and method for treating nsclc by inhalation | |
| Allen | Are inhaled systemic therapies a viable option for the treatment of the elderly patient? | |
| TW200305447A (en) | Methods and compositions for treating respiratory pathologies | |
| Tronde | Pulmonary drug absorption: in vitro and in vivo investigations of drug absorption across the lung barrier and its relation to drug physicochemical properties | |
| Everard et al. | In vitro assessment of drug delivery through an endotracheal tube using a dry powder inhaler delivery system. | |
| JPWO2020214644A5 (enExample) | ||
| Rashad et al. | Performance of different add-on devices in dual limb non-invasive mechanically ventilated circuit | |
| Fahad et al. | Mechanism and Ways of Pulmonary Drug Administration | |
| CN102247380A (zh) | 一种以布地奈德与茚达特罗为活性成分的复方制剂 | |
| CN101548952B (zh) | 一种山莨菪碱干粉吸入剂及其制备方法和应用 | |
| Clark et al. | The application of pulmonary inhalation technology to drug discovery |